Table 2.
Comparative MICs of dalbavancin and other antimicrobials against selected Gram-positive and anaerobic organisms
MIC90 range (μg/ml)* | ||||||
---|---|---|---|---|---|---|
Organism | Dalbavancin | Vancomycin | Linezolid | Teicoplanin | Quin/dalfo | Daptomycin |
Staphylococcus aureus (25, 40, 42) | 0.06 | 1 | ≤ 2 | 2 | 0.5 | NA |
Methicillin susceptible (25, 27, 41, 43, 44, 47, 48) | 0.06–0.5 | 1 | 1–4 | 2–4 | 0.25–0.5 | 0.5 |
Methicillin resistant (25, 27, 41, 43, 44, 47, 48) | 0.06–1 | 1–4 | 0.5–8 | 2–4 | 0.5 | 0.5 |
Glycopeptide intermediate (25, 39, 41) | 1–2 | 8 | 8–16 | 2 | 1 | NA |
Staphylococcus coagulase negative (25, 40, 42) | 0.06–0.12 | 2 | 4–8 | 1–2 | 0.5 | NA |
Methicillin susceptible† (25, 27, 43, 44, 47, 48) | 0.06–0.5 | 2 | 2–8 | 1–2 | 0.25–0.5 | 0.5 |
Methicillin resistant† (25, 27, 43, 44, 47, 48) | 0.06–0.5 | 2–4 | 2–16 | 1–2 | 0.5–1 | 0.5 |
Vancomycin non-susceptible (25) | 1 | 8 | > 32 | 2 | 0.5 | NA |
Teicoplanin resistant (39, 45) | 0.25 | 2 | NA | 1 | 1 | NA |
Staphylococcus epidermidis | ||||||
Methicillin susceptible (27, 41) | 0.25–0.5 | 1–2 | 8 | NA | NA | NA |
Methicillin resistant (27, 41) | 0.25 | 2–4 | 16 | NA | NA | NA |
Staphylococcus haemolyticus | ||||||
Methicillin susceptible (27) | 0.13 | 2 | 32 | NA | NA | 2 |
Methicillin resistant (27) | 0.5 | 4 | 32 | NA | NA | NA |
Streptococcus pneumoniae (25, 40, 42, 44, 46) | < 0.03–0.06 | 0.5 | 0.125 to ≤ 2 | 1–2 | < 0.5–1 | NA |
Penicillin susceptible (25, 27, 48) | 0.03–0.06 | 0.5 | 0.06 | 1 | 0.5 | NA |
Penicillin non-susceptible‡ (25, 27, 38, 48) | ≤ 0.016–0.03 | 0.5 | 0.06 | 1 | 0.5–1 | NA |
Streptococcus pyogenes (25) | 0.015 | 0.5 | 0.06 | 1 | ≤ 0.12 | NA |
Erythromycin susceptible (25) | 0.015 | 0.5 | 0.06 | 1 | ≤ 0.12 | NA |
Erythromycin resistant (25) | 0.015 | 0.5 | 0.06 | 1 | ≤ 0.12 | NA |
Viridans group streptococci (25, 40, 42, 44) | 0.016–0.03 | 1 | ≤ 2 | 1 | 0.5–1 | NA |
Penicillin susceptible (25, 48) | 0.03 | 1 | 0.06 | 1 | 1 | NA |
Penicillin non-susceptible (25, 48) | 0.03 | 0.5–1 | 0.12 | 1 | 1 | NA |
Erythromycin susceptible (25) | 0.03 | 1 | 0.06 | 1 | 1 | NA |
Erythromycin resistant (25) | 0.03 | 1 | 0.12 | 1 | 1 | NA |
β-Haemolytic streptococci (25, 40, 42, 44, 48) | 0.015–0.06 | 0.5 | ≤ 2 | 1 | 0.5 | NA |
Streptococcus agalactiae (25) | 0.015 | 0.5 | 0.12 | 1 | 0.25 | NA |
Enterococcus spp. (40, 42) | 0.12–16 | 2 to > 16 | ≤ 2 to > 16 | 2 | > 2 | NA |
Vancomycin susceptible (44) | 0.5 | 2 | 0.5 | NA | > 8 | NA |
Vancomycin resistant (44) | 32 | > 16 | > 16 | NA | > 8 | NA |
vanA resistant (27, 38) | 32 to > 128 | > 128 | > 128 | NA | NA | NA |
vanB resistant (27) | 0.12–1 | 128 | ≤ 2 | 2 | 8 | NA |
Enterococcus faecalis | ||||||
Vancomycin susceptible (48) | 0.06 | NA | 0.5 | 2 | > 8 | NA |
Vancomycin resistant (38, 48) | 32 | NA | > 16 | 2 | > 8 | NA |
Enterococcus faecium | ||||||
Vancomycin susceptible (48) | 0.12 | NA | 0.5 | 2 | 2 | NA |
Vancomycin resistant (38, 48) | 32 | NA | > 16 | 2 | 1 | NA |
Quin/dalfo resistant (38) | 0.12§–8¶ | NA | NA | 2 | NA | NA |
Actinomyces spp. (28) | 0.5 | 1 | NA | 1 | 0.25 | 16 |
Bacillus spp. (44) | 0.25 | 1 | 2 | NA | 2 | NA |
Clostridium spp. (28) | 0.5 | 2 | NA | 4 | 0.5 | 8 |
Clostridium difficile (28) | 0.25 | 2 | NA | 8 | 4 | 2 |
Clostridium perfringens(28) | 0.125 | 0.5 | NA | 2 | 0.5 | 1 |
Corynebacterium spp.(28, 44, 48) | ≤ 0.03–0.5 | 0.5–1 | 0.5 | 1 | 0.5–1 | 8 |
Corynebacterium jeikeium (28) | 0.5 | 0.5 | NA | 0.5 | 0.5 | 0.25 |
Lactobacillus spp. (48) | > 32 | > 32 | NA | 8 | 2 | > 32 |
Listeria spp. (40) | 0.06 | NA | NA | NA | NA | NA |
Peptostreptococcus spp. (28) | 0.25 | 0.5 | NA | 2 | 0.5 | 1 |
Propionibacterium spp. (28) | 0.5 | 1 | NA | 1 | 0.2 | 16 |
Permission for reprint granted by Ann Pharmocother; 2006; 40: 449–60.
MIC90 range based on MIC90 values reported in different studies that compared dalbavancin with at least one of the comparator agents.
Data from Ref. (27) includes other coagulase-negative staphylococci, but do not include Staphylococcus epidermidis and Staphylococcus haemolyticus.
Includes penicillin-non-susceptible, penicillin-intermediate and penicillin-resistant isolates.
vanA negative isolates.
vanA positive isolates. MICs, minimum inhibitory concentrations; NA, not available; quin/dalfo, quinupristin/dalfopristin; vanA, vancomycin-resistant enterococci possessing the vanA gene.